The Indian Pharmacopoeia Commission, an autonomous institution under the Ministry of Health and Family Welfare, Government of India, organized a Scientific Conclave and Interactive Session on Indian Pharmacopoeia (IP) 2026 in Haridwar on the theme, “Strengthening Pharmaceutical Manufacturing through Pharmacopoeial Standards and Quality Compliance.”

The event was held in collaboration with the Association of Devbhumi Pharma Industries and affiliated pharmaceutical manufacturing associations of Uttarakhand, with the objective of enhancing awareness about the provisions of IP 2026 and promoting quality compliance across the pharmaceutical manufacturing sector.

Recognizing the state's significant contribution to pharmaceutical manufacturing, IPC organized the conclave to strengthen industry awareness, facilitate compliance with pharmacopoeial requirements, and support the consistent adoption of IP standards across the pharmaceutical sector.

The programme brought together representatives from pharmaceutical manufacturing companies, quality control and quality assurance teams, regulatory authorities, analytical scientists, and personnel from drug testing laboratories to discuss recent developments in pharmacopoeial standards and their implementation.

Sandeep Jain, Chairman of ADPI, emphasized the importance of collaboration between industry and standard-setting organizations in strengthening pharmaceutical quality systems.

Sidharth Sahai Malhotra, Assistant Drugs Controller (India), CDSCO, Dehradun, and Tajber Singh, Drug Controller and State Licensing Authority, Uttarakhand highlighted the critical role of pharmacopoeial standards in ensuring regulatory compliance and protecting public health.

Delivering the Chief Guest address, V. Kalaiselvan, Secretary-cum-Scientific Director, IPC, underscored the importance of the Indian Pharmacopoeia in establishing scientifically validated quality standards for medicines and supporting India's emergence as a global pharmaceutical leader.